Neuro Health Centrum s.r.o.
- Address
- lock Available on a paid plan
Neuro Health Centrum s.r.o. - Alzheimer's Disease Research Center
Neuro Health Centrum s.r.o. is a specialized clinical research facility dedicated to advancing the understanding and treatment of Alzheimer's disease and related cognitive disorders. The center demonstrates exceptional expertise in conducting complex Phase 2 and Phase 3 clinical trials, focusing on both cognitive decline and behavioral manifestations of neurodegenerative conditions. With a comprehensive approach to Alzheimer's disease research, the facility evaluates novel therapeutic interventions across the entire disease spectrum, from early-stage cognitive impairment to more advanced dementia.
- Mild Cognitive Impairment (MCI) and early-stage Alzheimer's disease interventions, including innovative oral medications and neuroprotective agents
- Behavioral and Psychological Symptoms of Dementia (BPSD), particularly psychosis and agitation associated with Alzheimer's disease
- Long-term safety and efficacy studies with extended follow-up protocols
- Novel pharmacological mechanisms including muscarinic receptor modulators and metabolic interventions
The center's research portfolio encompasses cutting-edge therapeutic approaches targeting multiple aspects of Alzheimer's pathology and symptomatology. Their experience includes evaluating cognitive and functional outcomes using validated assessment tools such as the Clinical Dementia Rating Scale (CDR-SB), BEHAVE-AD psychosis subscale, and Cohen-Mansfield Agitation Inventory (CMAI-IPA). The facility's participation in both short-term efficacy trials and open-label extension studies demonstrates their commitment to understanding both immediate therapeutic benefits and long-term safety profiles of investigational treatments for this challenging patient population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Neuro Health Centrum s.r.o.
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 1) | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 4 | Unknown | 2025-08-25 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.